HMGXB4 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Jurkat T-lymphocyte line, engineered to disrupt the HMGXB4 gene. This product provides a loss-of-function model for studying the role of HMGXB4 in transcriptional regulation and WNT/??-catenin signaling. The polyclonal nature offers a heterogeneous pool of edited alleles, suitable for pooled functional assays.
Jurkat cells are an immortalized human T-cell line established from the peripheral blood of a 14-year-old male with acute T-cell leukemia. Widely employed in immunology and cancer research, Jurkat cells serve as a model system for T-cell signaling, activation, and apoptosis. Their leukemic origin and robust growth make them a convenient platform for investigating oncogenic mechanisms and drug responses.
HMGXB4 encodes a transcription factor that functions as a negative regulator of canonical WNT/??-catenin signaling. It contains an HMG-box domain that mediates DNA binding and protein interactions. HMGXB4 directly binds ??-catenin, thereby preventing its association with TCF/LEF transcription factors such as TCF7 and LEF1. Consequently, HMGXB4 represses WNT target gene expression, including MYC, CCND1, and AXIN2. Upstream of HMGXB4, WNT ligands like WNT3A activate Frizzled receptors and LRP5/6 co-receptors, leading to Dishevelled-mediated inhibition of GSK-3??, which stabilizes ??-catenin. Through this mechanism, HMGXB4 modulates cell cycle progression and apoptosis, particularly in T lymphocytes.
Within the Jurkat T-cell context, disruption of HMGXB4 is expected to abrogate its repressive function, resulting in enhanced ??-catenin/TCF transcriptional activity and increased expression of WNT target genes. This can modulate proliferation, survival, and potentially differentiation pathways, providing insights into the role of WNT signaling in T-cell leukemia and immune cell biology. Given that Jurkat cells are derived from an acute T-cell leukemia patient, the model is particularly relevant for studying how aberrant WNT pathway activation contributes to leukemogenesis and for identifying therapeutic vulnerabilities.
This polyclonal knockout cell pool is well-suited for a range of experimental applications. Researchers can quantify changes in WNT target gene expression using RT-qPCR, assess ??-catenin signaling activity with TOPFlash/FOPFlash luciferase reporter assays, and probe HMGXB4?C??-catenin interactions through co-immunoprecipitation. Western blotting can measure ??-catenin protein levels and downstream effectors, while flow cytometry enables analysis of cell cycle distribution and apoptosis. Applications include dissecting negative regulation of WNT signaling, validating drug targets, and exploring transcriptional repression mechanisms in T-cell malignancies. For further details or to inquire about this product, please contact Ascent Research.
